Literature DB >> 2845134

Structural analysis of a hepatitis B virus genome integrated into chromosome 17p of a human hepatocellular carcinoma.

Y Z Zhou1, B L Slagle, L A Donehower, P vanTuinen, D H Ledbetter, J S Butel.   

Abstract

Hepatitis B virus (HBV) is clearly a factor in the development of hepatocellular carcinoma, but its mechanism of action remains obscure. One possibility is that the HBV integration event alters the expression of a nearby growth-regulatory cellular gene. A 9-kilobase (kb) DNA fragment containing an HBV insert plus flanking cellular sequences was cloned from a hepatoma specimen from Shanghai, People's Republic of China. Restriction mapping of the insert revealed a large inverted repeat structure consisting of both viral sequences (encompassing all of the core and pre-S regions and portions of the X and S genes) and at least 3 kb of unique cellular sequences. The virus-cell junction mapped 11 nucleotides from the DR1 region, in a position within the HBV X gene and included in the cohesive overlap region. A probe generated from 1.0 kb of the flanking cellular DNA mapped the viral insert to chromosome 17 in the region designated 17p11.2-17p12, which is near the human proto-oncogene p53. Sequence data from a portion of the flanking cellular DNA revealed a stretch of approximately 70 base pairs that showed highly significant homology with a conserved region of a number of functional mammalian DNAs, including the human autonomously replicating sequence 1 (ARS1).

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2845134      PMCID: PMC253855     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  48 in total

1.  Participation of p53 cellular tumour antigen in transformation of normal embryonic cells.

Authors:  D Eliyahu; A Raz; P Gruss; D Givol; M Oren
Journal:  Nature       Date:  1984 Dec 13-19       Impact factor: 49.962

2.  Cloning and restriction mapping of human HBV genome serotype adr.

Authors:  X F Wu; Y Z Zhou; Z M Feng; Z P Li; S Y Xia
Journal:  Sci Sin B       Date:  1983-09

3.  Inversely repeating integrated hepatitis B virus DNA and cellular flanking sequences in the human hepatoma-derived cell line huSP.

Authors:  H Mizusawa; M Taira; K Yaginuma; M Kobayashi; E Yoshida; K Koike
Journal:  Proc Natl Acad Sci U S A       Date:  1985-01       Impact factor: 11.205

4.  Hepatitis B virus integration in hepatocellular carcinoma DNA: duplication of cellular flanking sequences at the integration site.

Authors:  K Yaginuma; M Kobayashi; E Yoshida; K Koike
Journal:  Proc Natl Acad Sci U S A       Date:  1985-07       Impact factor: 11.205

5.  Hybrid hepatitis B virus-host transcripts in a human hepatoma cell.

Authors:  J Ou; W J Rutter
Journal:  Proc Natl Acad Sci U S A       Date:  1985-01       Impact factor: 11.205

6.  Specific hepatitis B virus integration in hepatocellular carcinoma DNA through a viral 11-base-pair direct repeat.

Authors:  A Dejean; P Sonigo; S Wain-Hobson; P Tiollais
Journal:  Proc Natl Acad Sci U S A       Date:  1984-09       Impact factor: 11.205

7.  Complete nucleotide sequence of hepatitis B virus DNA of subtype adr and its conserved gene organization.

Authors:  M Kobayashi; K Koike
Journal:  Gene       Date:  1984-10       Impact factor: 3.688

8.  Integration of hepatitis B virus DNA: evidence for integration in the single-stranded gap.

Authors:  R Koshy; S Koch; A F von Loringhoven; R Kahmann; K Murray; P H Hofschneider
Journal:  Cell       Date:  1983-08       Impact factor: 41.582

9.  Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation.

Authors:  L F Parada; H Land; R A Weinberg; D Wolf; V Rotter
Journal:  Nature       Date:  1984 Dec 13-19       Impact factor: 49.962

10.  Co-transcribed 3' host sequences augment expression of integrated hepatitis B virus DNA.

Authors:  A F von Loringhoven; S Koch; P H Hofschneider; R Koshy
Journal:  EMBO J       Date:  1985-01       Impact factor: 11.598

View more
  14 in total

1.  Prototypic sequences for human repetitive DNA.

Authors:  J Jurka; J Walichiewicz; A Milosavljevic
Journal:  J Mol Evol       Date:  1992-10       Impact factor: 2.395

Review 2.  Molecular virology of hepatitis B virus for clinicians.

Authors:  Timothy M Block; Haitao Guo; Ju-Tao Guo
Journal:  Clin Liver Dis       Date:  2007-11       Impact factor: 6.126

Review 3.  Hepatitis B virus. New and evolving issues.

Authors:  B Yoffe; C A Noonan
Journal:  Dig Dis Sci       Date:  1992-01       Impact factor: 3.199

4.  Abnormal structure and expression of p53 gene in human hepatocellular carcinoma.

Authors:  B Bressac; K M Galvin; T J Liang; K J Isselbacher; J R Wands; M Ozturk
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

5.  Effects of hepatitis B virus infection on human sperm chromosomes.

Authors:  Jian-Min Huang; Tian-Hua Huang; Huan-Ying Qiu; Xiao-Wu Fang; Tian-Gang Zhuang; Hong-Xi Liu; Yong-Hua Wang; Li-Zhi Deng; Jie-Wen Qiu
Journal:  World J Gastroenterol       Date:  2003-04       Impact factor: 5.742

6.  Chromosomal sites for hepatitis B virus integration in human hepatocellular carcinoma.

Authors:  T Tokino; K Matsubara
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

7.  MIRs are classic, tRNA-derived SINEs that amplified before the mammalian radiation.

Authors:  A F Smit; A D Riggs
Journal:  Nucleic Acids Res       Date:  1995-01-11       Impact factor: 16.971

8.  Hepatitis B virus transactivator X protein is not tumorigenic in transgenic mice.

Authors:  T H Lee; M J Finegold; R F Shen; J L DeMayo; S L Woo; J S Butel
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

9.  The hepatitis B virus pre-S/S(t) transactivator is generated by 3' truncations within a defined region of the S gene.

Authors:  U Lauer; L Weiss; P H Hofschneider; A S Kekulé
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

Review 10.  Hepatitis B virus infection and primary hepatocellular carcinoma.

Authors:  M Feitelson
Journal:  Clin Microbiol Rev       Date:  1992-07       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.